Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial)

Richard Dodel, Annika Spottke, Alexander Gerhard, Alexander Reuss, Sylvia Reinecker, Nicole Schimke, Claudia Trenkwalder, Friederike Sixel-Döring, Birgit Herting, Christoph Kamm, Thomas Gasser, Martin Sawires, Felix Geser, Martin Köllensperger, Klaus Seppi, Manja Kloss, Martin Krause, Christine Daniels, Günther Deuschl, Silke BöttgerMarkus Naumann, Axel Lipp, Doreen Gruber, Andreas Kupsch, Yansheng Du, Federico Turkheimer, David J. Brooks, Thomas Klockgether, Werner Poewe, Gregor Wenning, Carmen Schade-Brittinger, Wolfgang H. Oertel, Karla Eggert

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

The aim of the study was to investigate the effi-cacy of the antibiotic minocycline as a drug treatment in patients with Multiple-System-Atrophy Parkinson-type (MSA-P). Sixty-three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple-System- Atrophy Rating-Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified-Parkinson's-Disease Rating-Scale (UPDRS). Healthrelated quality of life (HrQoL) was assessed using the EQ-5D and SF-12. "Progression rate" was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow-up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. "progression rate" was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5) [11C](R)-PK11195-PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)-PK11195 binding actually decreased. These preliminary PET-data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function.

Original languageEnglish
Pages (from-to)97-107
Number of pages11
JournalMovement Disorders
Volume25
Issue number1
DOIs
StatePublished - Jan 15 2010

Fingerprint

Multiple System Atrophy
Minocycline
Placebos
Therapeutics
Quality of Life
Double-Blind Method
Parkinson Disease
(R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide
Anti-Bacterial Agents
Pharmaceutical Preparations

Keywords

  • Minocycline
  • Multiple system atrophy
  • PET

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Dodel, R., Spottke, A., Gerhard, A., Reuss, A., Reinecker, S., Schimke, N., ... Eggert, K. (2010). Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial). Movement Disorders, 25(1), 97-107. https://doi.org/10.1002/mds.22732

Minocycline 1-year therapy in multiple-system-atrophy : Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial). / Dodel, Richard; Spottke, Annika; Gerhard, Alexander; Reuss, Alexander; Reinecker, Sylvia; Schimke, Nicole; Trenkwalder, Claudia; Sixel-Döring, Friederike; Herting, Birgit; Kamm, Christoph; Gasser, Thomas; Sawires, Martin; Geser, Felix; Köllensperger, Martin; Seppi, Klaus; Kloss, Manja; Krause, Martin; Daniels, Christine; Deuschl, Günther; Böttger, Silke; Naumann, Markus; Lipp, Axel; Gruber, Doreen; Kupsch, Andreas; Du, Yansheng; Turkheimer, Federico; Brooks, David J.; Klockgether, Thomas; Poewe, Werner; Wenning, Gregor; Schade-Brittinger, Carmen; Oertel, Wolfgang H.; Eggert, Karla.

In: Movement Disorders, Vol. 25, No. 1, 15.01.2010, p. 97-107.

Research output: Contribution to journalArticle

Dodel, R, Spottke, A, Gerhard, A, Reuss, A, Reinecker, S, Schimke, N, Trenkwalder, C, Sixel-Döring, F, Herting, B, Kamm, C, Gasser, T, Sawires, M, Geser, F, Köllensperger, M, Seppi, K, Kloss, M, Krause, M, Daniels, C, Deuschl, G, Böttger, S, Naumann, M, Lipp, A, Gruber, D, Kupsch, A, Du, Y, Turkheimer, F, Brooks, DJ, Klockgether, T, Poewe, W, Wenning, G, Schade-Brittinger, C, Oertel, WH & Eggert, K 2010, 'Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial)', Movement Disorders, vol. 25, no. 1, pp. 97-107. https://doi.org/10.1002/mds.22732
Dodel, Richard ; Spottke, Annika ; Gerhard, Alexander ; Reuss, Alexander ; Reinecker, Sylvia ; Schimke, Nicole ; Trenkwalder, Claudia ; Sixel-Döring, Friederike ; Herting, Birgit ; Kamm, Christoph ; Gasser, Thomas ; Sawires, Martin ; Geser, Felix ; Köllensperger, Martin ; Seppi, Klaus ; Kloss, Manja ; Krause, Martin ; Daniels, Christine ; Deuschl, Günther ; Böttger, Silke ; Naumann, Markus ; Lipp, Axel ; Gruber, Doreen ; Kupsch, Andreas ; Du, Yansheng ; Turkheimer, Federico ; Brooks, David J. ; Klockgether, Thomas ; Poewe, Werner ; Wenning, Gregor ; Schade-Brittinger, Carmen ; Oertel, Wolfgang H. ; Eggert, Karla. / Minocycline 1-year therapy in multiple-system-atrophy : Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial). In: Movement Disorders. 2010 ; Vol. 25, No. 1. pp. 97-107.
@article{6d414330370b4000bcbc6f12a04a1e16,
title = "Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial)",
abstract = "The aim of the study was to investigate the effi-cacy of the antibiotic minocycline as a drug treatment in patients with Multiple-System-Atrophy Parkinson-type (MSA-P). Sixty-three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple-System- Atrophy Rating-Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified-Parkinson's-Disease Rating-Scale (UPDRS). Healthrelated quality of life (HrQoL) was assessed using the EQ-5D and SF-12. {"}Progression rate{"} was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow-up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. {"}progression rate{"} was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5) [11C](R)-PK11195-PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)-PK11195 binding actually decreased. These preliminary PET-data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function.",
keywords = "Minocycline, Multiple system atrophy, PET",
author = "Richard Dodel and Annika Spottke and Alexander Gerhard and Alexander Reuss and Sylvia Reinecker and Nicole Schimke and Claudia Trenkwalder and Friederike Sixel-D{\"o}ring and Birgit Herting and Christoph Kamm and Thomas Gasser and Martin Sawires and Felix Geser and Martin K{\"o}llensperger and Klaus Seppi and Manja Kloss and Martin Krause and Christine Daniels and G{\"u}nther Deuschl and Silke B{\"o}ttger and Markus Naumann and Axel Lipp and Doreen Gruber and Andreas Kupsch and Yansheng Du and Federico Turkheimer and Brooks, {David J.} and Thomas Klockgether and Werner Poewe and Gregor Wenning and Carmen Schade-Brittinger and Oertel, {Wolfgang H.} and Karla Eggert",
year = "2010",
month = "1",
day = "15",
doi = "10.1002/mds.22732",
language = "English",
volume = "25",
pages = "97--107",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Minocycline 1-year therapy in multiple-system-atrophy

T2 - Effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial)

AU - Dodel, Richard

AU - Spottke, Annika

AU - Gerhard, Alexander

AU - Reuss, Alexander

AU - Reinecker, Sylvia

AU - Schimke, Nicole

AU - Trenkwalder, Claudia

AU - Sixel-Döring, Friederike

AU - Herting, Birgit

AU - Kamm, Christoph

AU - Gasser, Thomas

AU - Sawires, Martin

AU - Geser, Felix

AU - Köllensperger, Martin

AU - Seppi, Klaus

AU - Kloss, Manja

AU - Krause, Martin

AU - Daniels, Christine

AU - Deuschl, Günther

AU - Böttger, Silke

AU - Naumann, Markus

AU - Lipp, Axel

AU - Gruber, Doreen

AU - Kupsch, Andreas

AU - Du, Yansheng

AU - Turkheimer, Federico

AU - Brooks, David J.

AU - Klockgether, Thomas

AU - Poewe, Werner

AU - Wenning, Gregor

AU - Schade-Brittinger, Carmen

AU - Oertel, Wolfgang H.

AU - Eggert, Karla

PY - 2010/1/15

Y1 - 2010/1/15

N2 - The aim of the study was to investigate the effi-cacy of the antibiotic minocycline as a drug treatment in patients with Multiple-System-Atrophy Parkinson-type (MSA-P). Sixty-three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple-System- Atrophy Rating-Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified-Parkinson's-Disease Rating-Scale (UPDRS). Healthrelated quality of life (HrQoL) was assessed using the EQ-5D and SF-12. "Progression rate" was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow-up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. "progression rate" was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5) [11C](R)-PK11195-PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)-PK11195 binding actually decreased. These preliminary PET-data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function.

AB - The aim of the study was to investigate the effi-cacy of the antibiotic minocycline as a drug treatment in patients with Multiple-System-Atrophy Parkinson-type (MSA-P). Sixty-three patients were randomized to minocycline 200 mg/d (n = 32) or a matching placebo (n = 31). The primary outcome variable was the change in the value of the motor score of the Unified Multiple-System- Atrophy Rating-Scale (UMSARSII) from baseline to 48 weeks. Secondary outcome variables included subscores and individual Parkinsonian symptoms as determined by the UMSARS and the Unified-Parkinson's-Disease Rating-Scale (UPDRS). Healthrelated quality of life (HrQoL) was assessed using the EQ-5D and SF-12. "Progression rate" was assumed to be reflected in the change in motor function over 48 weeks. At 24 weeks and 48 weeks of follow-up, there was a significant deterioration in motor scores in both groups, but neither the change in UMSARSII nor in UPDRSIII differed significantly between treatment groups, i.e. "progression rate" was considered to be similar in both treatment arms. HrQoL did not differ among the two treatment arms. In a small subgroup of patients (n = 8; minocycline = 3, placebo = 5) [11C](R)-PK11195-PET was performed. The three patients in the minocycline group had an attenuated mean increase in microglial activation as compared to the placebo group (P = 0.07) and in two of them individually showed decreased [11C](R)-PK11195 binding actually decreased. These preliminary PET-data suggest that minocycline may interfere with microglial activation. The relevance of this observation requires further investigation. This prospective, 48 week, randomized, double-blind, multinational study failed to show a clinical effect of minocycline on symptom severity as assessed by clinical motor function.

KW - Minocycline

KW - Multiple system atrophy

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=75749146196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75749146196&partnerID=8YFLogxK

U2 - 10.1002/mds.22732

DO - 10.1002/mds.22732

M3 - Article

C2 - 20014118

AN - SCOPUS:75749146196

VL - 25

SP - 97

EP - 107

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 1

ER -